1 |
NCT01407497 |
Completed |
Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine |
|
- Biological: DNA HIVIS and MVA-CMDR
- Biological: Saline solution
|
Interventional |
Phase 1 |
- Instituto Nacional de Saúde, Mozambique
- Swedish Institute for Communicable Disease Control, Sweden
- European and Developing Countries Clinical Trials Partnership (EDCTP)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Adverse events (local and system reactogenicity)
- Immunogenicity
|
25 |
All |
18 Years to 26 Years (Adult) |
NCT01407497 |
TAMOVAC-01-MZ |
|
August 2011 |
March 2013 |
August 2013 |
August 2, 2011 |
December 4, 2013 |
|
- Centro de Investigação e Treino em Saúde de Polana Caniço
Maputo, Mozambique
|
2 |
NCT01520844 |
Recruiting |
the ANRS CO21 " Extreme " Cohort (CODEX) |
|
- Biological: blood sampling
|
Interventional |
Not Applicable |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- clinical and immuno-virological
- mechanisms leading to the virus control and CD4 homeostasy with physiopathological studies
- impact of a prolonged untreated HIV infection,
- (and 2 more...)
|
300 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01520844 |
ANRS CO21 CODEX |
CODEX |
February 2012 |
February 2018 |
September 2019 |
January 30, 2012 |
March 22, 2017 |
|
- Lambotte
Kremlin Bicetre, France
|
3 |
NCT01407237 |
Completed |
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV |
|
- Drug: Angiotensin II Infusion
|
Observational |
|
- Massachusetts General Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- 24-hour urine aldosterone to creatinine ratio
- Plasma Renin Activity
- Aldosterone response to Angiotensin II Infusion
- (and 4 more...)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT01407237 |
2011P000250 |
|
January 2012 |
March 2015 |
|
August 2, 2011 |
August 5, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
4 |
NCT01406626 |
Unknown † |
Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care |
|
- Behavioral: Health Navigator
|
Interventional |
Not Applicable |
- University of California, Los Angeles
- Los Angeles County Department of Public Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Linkage to HIV Care
- Retention in Treatment
- Adherence to Treatment
- (and 2 more...)
|
360 |
Male |
18 Years and older (Adult, Senior) |
NCT01406626 |
R01DA030781 |
LINK LA |
December 2012 |
January 2016 |
June 2016 |
August 1, 2011 |
January 20, 2016 |
|
- LA County Jail
Los Angeles, California, United States
|
5 |
NCT01417949 |
Completed |
Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events |
|
- Other: Time of starting antiretroviral therapy
|
Interventional |
Phase 4 |
- Universitätsklinikum Hamburg-Eppendorf
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Death, all new/relapsing opportunistic infections and other grade 4 clinical endpoints within 24 weeks after randomization
- Hospitalization days after completion of initial OI treatment between both groups
- incidence of immune reconstitution inflammatory syndrome
- (and 4 more...)
|
61 |
All |
18 Years and older (Adult, Senior) |
NCT01417949 |
EudraCT Nr. 2010-022413-26 |
IDEAL |
August 2011 |
May 2015 |
May 2015 |
August 16, 2011 |
November 28, 2016 |
|
- Vivantes Auguste-Viktoria-Klinikum
Berlin, Germany - Charitè Universitätsmedizin Berlin Campus Virchow Klinikum
Berlin, Germany - Universitätsklinikum Bonn, Innere Medizin I, Immunologische Ambulanz/Studienzentrale
Bonn, Germany - (and 14 more...)
|
6 |
NCT01411839 |
Completed Has Results |
Depression and ART Adherence in HIV+ Latinos |
- Depressive Symptoms
- HIV Infections
|
- Behavioral: Cognitive-Behavioral Therapy (CBT-AD)
|
Interventional |
Not Applicable |
- University of Washington
- National Institute of Mental Health (NIMH)
- University of Texas
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a
- Self-Report Adherence
- MedSignals Electronic Pill-box for Adherence
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT01411839 |
35279 R34MH084674 |
|
July 2008 |
August 2011 |
January 2012 |
August 8, 2011 |
March 19, 2018 |
March 19, 2018 |
- Centro de Salud Familiar La Fe CARE Center
El Paso, Texas, United States
|
7 |
NCT01409655 |
Completed |
Centralized Off-Site Adherence Enhancement Program |
- HIV/AIDS, Medication Adherence
|
- Behavioral: cognitive-behavioral therapy
|
Interventional |
Not Applicable |
- University of California, Los Angeles
- Yale University
- Harbor Medical Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- change of adherence to antiretroviral medications measured at weeks 0, 4, 8, 12, 16, 20, and 24
|
42 |
All |
18 Years and older (Adult, Senior) |
NCT01409655 |
R34DA031643 |
CARE |
August 2011 |
November 2014 |
November 2014 |
August 4, 2011 |
February 25, 2016 |
|
- University of California, Los Angeles
Los Angeles, California, United States
|
8 |
NCT01420523 |
Terminated |
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy |
- Human Immunodeficiency Virus
- Lipohypertrophy
|
- Drug: Raltegravir-Maraviroc
|
Interventional |
Phase 2 |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Merck Sharp & Dohme Corp.
- ViiV Healthcare
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Virological failure
- Viro-immunological efficacy
- Tolerability criteria and metabolic impact
- (and 2 more...)
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT01420523 |
2011-002483-24 |
ROCnRAL |
December 2011 |
April 2013 |
April 2013 |
August 19, 2011 |
July 24, 2015 |
|
- Hôpital Pitié Salpétrière
Paris, France
|
9 |
NCT01417988 |
Terminated |
Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment |
- HIV Infection
- Tuberculosis
|
- Drug: Experimental: Empiric TB treatment
- Drug: ART only arm
|
Interventional |
Phase 4 |
- Prof JMA Lange
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- All-cause mortality in the first 24 weeks after initiation of ART
- CD4 T cell absolute increase
- Causes of death
- (and 3 more...)
|
44 |
All |
18 Years and older (Adult, Senior) |
NCT01417988 |
AIGHD_001 |
PrOMPT |
August 2011 |
June 2013 |
June 2013 |
August 16, 2011 |
February 17, 2014 |
|
- Medical Research Unit, Albert Schweitzer Hospital
Lambaréné, Gabon - Ministry of Health -Provincial Heatlh Directorate of the Sofala Province (Direcção Provincial de Saúde de Sofala DPSS)
Beira, Mozambique - Infectious Diseases Institute University Makarere
Kampala, Uganda
|
10 |
NCT01413529 |
Completed |
HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users |
|
- Behavioral: HEART to HAART
- Behavioral: adherence counseling with the addition of smartphone control
|
Interventional |
Phase 2 |
- University of Maryland
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- adherence to antiretroviral medication
|
35 |
All |
18 Years to 65 Years (Adult) |
NCT01413529 |
HP-00049374 1R34DA032411 |
|
September 2011 |
April 2015 |
April 2015 |
August 10, 2011 |
August 22, 2017 |
|
- Jacques Initiative
Baltimore, Maryland, United States
|
11 |
NCT01403792 |
Completed |
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects |
- Human Immunodeficiency Virus
|
|
Interventional |
Phase 1 |
- University of Surrey
- European Commission
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Occurrence, intensity and relationship to P2G12 administration of local and general adverse events (AEs) throughout the study period after drug administration.
- Changes in levels of P2G12 in blood and vaginal secretions as compared to baseline.
|
11 |
Female |
18 Years to 50 Years (Adult) |
NCT01403792 |
CRC282 |
|
June 2011 |
November 2011 |
November 2011 |
July 27, 2011 |
December 22, 2011 |
|
- Surrey Clinical Research Centre
Guildford, Surrey, United Kingdom
|
12 |
NCT01410058 |
Completed |
Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction |
|
- Dietary Supplement: Moringa oleifera
|
Observational |
|
- University of Zimbabwe
- State University of New York at Buffalo
- Biomedical Research and Training Institute
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Area under the plasma concentration time curve (AUC)
- clearance (CL)
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT01410058 |
MO 001 |
|
January 2013 |
September 2013 |
September 2013 |
August 4, 2011 |
December 3, 2014 |
|
- Parirenyatwa Hospital OI Clinic
Harare, Zimbabwe
|
13 |
NCT01414413 |
Completed Has Results |
Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi |
|
- Other: Home assessment and initiation of ART
- Other: Clinic-based ART assessment and initiation
|
Interventional |
Not Applicable |
- Liverpool School of Tropical Medicine
- University of Malawi College of Medicine
- London School of Hygiene and Tropical Medicine
- Ministry of Health and Population, Malawi
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- ART Initiation
- Uptake of Home-based HIV Testing
- Reporting of HIV-positive Results
- (and 3 more...)
|
16660 |
All |
18 Years and older (Adult, Senior) |
NCT01414413 |
MLW-089673 WT089673/B/09/Z |
CONDA-YAPA |
January 2012 |
November 2012 |
April 2013 |
August 11, 2011 |
April 7, 2014 |
April 7, 2014 |
- Malawi-Liverpool-Wellcome Trust Clinical Research Programme
Blantyre, Chichiri, Malawi
|
14 |
NCT01405456 |
Active, not recruiting |
Eplerenone in HIV Associated Abdominal Fat Accumulation |
|
- Drug: Eplerenone and lifestyle
- Other: placebo and lifestyle
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Insulin stimulated glucose uptake
- visceral adipose tissue
- liver fat
- (and 9 more...)
|
46 |
All |
30 Years to 65 Years (Adult) |
NCT01405456 |
2010P002095 |
|
January 2012 |
May 3, 2017 |
December 2017 |
July 29, 2011 |
May 17, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
15 |
NCT01404572 |
Completed Has Results |
Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects |
|
- Drug: Atazanavir (current formulation)
- Drug: Atazanavir, powder for oral use 1 (POU1)
- Drug: Atazanavir (POU2)
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
|
- Median Scores on a Subjective Sweet Intensity Scale for Current and New Powder for Oral Use (POU) Formulations of Atazanavir
- Mean Scores on a Subjective Sweet Intensity Scale for Current and New Powder for Oral Use (POU) Formulations of Atazanavir
- Median Palatability Score for Current and New Powder for Oral Use Formulations of Atazanavir
- (and 5 more...)
|
12 |
All |
18 Years to 49 Years (Adult) |
NCT01404572 |
AI424-466 |
|
August 2011 |
September 2011 |
September 2011 |
July 28, 2011 |
June 10, 2013 |
June 10, 2013 |
- Pra International
Lenexa, Kansas, United States
|
16 |
NCT01421485 |
Completed |
Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth |
|
- Behavioral: Integrated treatment program
- Behavioral: Treatment as Usual
|
Interventional |
Not Applicable |
- Rhode Island Hospital
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
|
170 |
All |
13 Years to 17 Years (Child) |
NCT01421485 |
1R01MH087520-01A2 |
ITP |
August 2011 |
April 2015 |
August 2016 |
August 22, 2011 |
October 4, 2016 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States
|
17 |
NCT01421368 |
Completed |
Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use |
|
- Drug: Tenofovir 1% vaginal gel
- Drug: Depo-medroxyprogesterone acetate (DMPA)
- Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Effect of oral contraceptives and DMPA on tenofovir PK, PD, and safety by comparing the following endpoints before initiation of contraceptive method and 10 weeks after initiation of contraceptive method
- Effect of the menstrual cycle of the tenofovir PK, PD, and safety by comparing the following endpoints 3 and 1 hours after insertion of 2 doses of study gel, in the follicular and luteal phases before initiating contraception
- To assess the effect of oral contraceptives and DMPA on markers of mucosal immunity by comparing the following endpoints (in the absence of tenofovir) before initiation of contraceptive method and 10 weeks after initiation of contraceptive method
|
72 |
Female |
18 Years to 50 Years (Adult) |
NCT01421368 |
A10-114 |
|
March 2012 |
March 2014 |
March 2014 |
August 22, 2011 |
April 10, 2015 |
|
- University of Pittsburgh School of Medicine, Center for Family Planning Research
Pittsburgh, Pennsylvania, United States - Easter Virginia Medical School
Norfolk, Virginia, United States - Profamilia
Santo Domingo, Dominican Republic
|
18 |
NCT01418014 |
Active, not recruiting |
Adolescent Master Protocol |
|
|
Observational |
|
- Harvard School of Public Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute on Drug Abuse (NIDA)
- (and 9 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Abnormal growth
- Delayed sexual maturation
- Abnormal bone mineral density
- (and 12 more...)
|
678 |
All |
7 Years and older (Child, Adult, Senior) |
NCT01418014 |
HD052102 - PH200 PH200 |
AMP |
March 2007 |
July 2020 |
July 2020 |
August 16, 2011 |
January 31, 2018 |
|
- University of California San Diego
La Jolla, California, United States - University of Colorado Denver Health Sciences Center
Aurora, Colorado, United States - Children's Diagnostic and Treatment Center
Fort Lauderdale, Florida, United States - (and 12 more...)
|
19 |
NCT01425099 |
Completed |
Drug Interaction Study Between Dolutegravir and Prednisone |
- Infection, Human Immunodeficiency Virus
|
- Drug: Dolutegravir
- Drug: Prednisone
|
Interventional |
Phase 1 |
- ViiV Healthcare
- Shionogi
- GlaxoSmithKline
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Composite of DTG pharmacokinetic parameters on Day 5 and Day 10: AUC(0-t), Cmax, C0, Ct, Cmin, CL/F, and t½.
- Safety and tolerability parameters as assessed by change from baseline in vital signs (BP and HR), number of subjects with adverse events and toxicity grading of clinical laboratory tests
|
12 |
All |
18 Years to 65 Years (Adult) |
NCT01425099 |
115696 |
|
September 2011 |
October 2011 |
October 2011 |
August 29, 2011 |
November 7, 2011 |
|
- GSK Investigational Site
Buffalo, New York, United States
|
20 |
NCT01404312 |
Completed |
Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection |
- Tuberculosis
- HIV Infections
|
- Drug: Rifapentine (RPT)
- Drug: Isoniazid (INH)
- Dietary Supplement: Pyridoxine (Vitamin B6)
|
Interventional |
Phase 3 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Time from randomization to first diagnosis of active TB
- Occurrence of one or more serious adverse events (SAEs) versus no SAEs
- Highest reported grade of each new Grade 3 or 4 laboratory value or sign or symptom that is at least one grade increase from baseline for targeted events
- (and 11 more...)
|
3000 |
All |
13 Years and older (Child, Adult, Senior) |
NCT01404312 |
A5279 10848 ACTG A5279 |
|
May 2012 |
November 14, 2017 |
November 14, 2017 |
July 28, 2011 |
December 4, 2017 |
|
- University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program
La Jolla, California, United States - University of Southern California CRS
Los Angeles, California, United States - UCSD Antiviral Research Center CRS
San Diego, California, United States - (and 42 more...)
|
21 |
NCT01403051 |
Completed Has Results |
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART |
|
- Drug: EFV/FTC/TDF
- Drug: Calcium Carbonate
- Drug: Vitamin D3
- (and 2 more...)
|
Interventional |
Phase 2 |
- AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The Percent Change From Baseline in Bone Mineral Density (BMD) at Total Hip
- The Percent Change From Baseline in Bone Mineral Density (BMD) at Spine
- Number of Participants With Primary Adverse Events
- (and 11 more...)
|
167 |
All |
18 Years and older (Adult, Senior) |
NCT01403051 |
ACTG A5280 1U01AI068636 |
|
September 2011 |
February 2013 |
February 2013 |
July 27, 2011 |
January 28, 2016 |
March 19, 2014 |
- Alabama Therapeutics CRS (5801)
Birmingham, Alabama, United States - Usc Crs (1201)
Los Angeles, California, United States - UCLA CARE Center CRS (601)
Los Angeles, California, United States - (and 36 more...)
|
22 |
NCT01400412 |
Completed Has Results |
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen |
|
- Drug: Darunavir
- Drug: Ritonavir
- Drug: Tenofovir disoproxil fumarate
- (and 4 more...)
|
Interventional |
Phase 2 |
- AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percent Change From Baseline in Total Hip Bone Mineral Density (BMD)
- Percent Change in Lumbar Spine Bone Mineral Density (BMD)
- Change in CD4 Count From Baseline to Week 24
- (and 17 more...)
|
262 |
All |
18 Years and older (Adult, Senior) |
NCT01400412 |
ACTG A5303 1U01AI068636 |
|
December 2011 |
June 2014 |
June 2014 |
July 22, 2011 |
February 22, 2018 |
July 15, 2015 |
- 31788 Alabama CRS
Birmingham, Alabama, United States - University of Southern California (1201)
Los Angeles, California, United States - UCLA CARE Center CRS (601)
Los Angeles, California, United States - (and 35 more...)
|
23 |
NCT01410344 |
Active, not recruiting |
Allogeneic Transplant in HIV Patients (BMT CTN 0903) |
|
- Drug: Fludarabine and Busulfan
- Drug: Fludarabine and Melphalan
- Drug: Busulfan and Fludarabine
- Drug: Cyclophosphamide and Total Body Irradiation
|
Interventional |
Phase 2 |
- Medical College of Wisconsin
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Non-Relapse Mortality
- Disease Status Following Transplant
- Chimerism
- (and 7 more...)
|
18 |
All |
15 Years and older (Child, Adult, Senior) |
NCT01410344 |
BMTCTN0903 U01HL069294 BMT CTN 0903 5U24CA076518 |
|
September 2011 |
June 2018 |
December 2018 |
August 5, 2011 |
March 21, 2018 |
|
- Mayo Clinic - Phoenix
Phoenix, Arizona, United States - City of Hope National Medical Center
Duarte, California, United States - University of CA, SF
San Francisco, California, United States - (and 8 more...)
|
24 |
NCT02006914 |
Completed |
Novel Therapy for Glucose Intolerance in HIV Disease |
|
- Dietary Supplement: Chromium Picolinate
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Chromium Picolinate supplementation
|
47 |
All |
18 Years and older (Adult, Senior) |
NCT02006914 |
R21AT002499 |
|
June 2005 |
May 2010 |
April 2012 |
December 10, 2013 |
December 10, 2013 |
|
- Stony Brook University Hospital GCRC
Stony Brook, New York, United States
|
25 |
NCT01410305 |
Completed |
Vitamin D and HIV-Cardiovascular Disease in Children and Young Adults |
|
|
Observational |
|
- University Hospitals Cleveland Medical Center
- Emory-Children's Center
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
290 |
All |
8 Years to 25 Years (Child, Adult) |
NCT01410305 |
1R01HD070490-01 |
|
September 2011 |
December 2014 |
December 2014 |
August 5, 2011 |
June 28, 2016 |
|
- Emory Chldren's Center
Atlanta, Georgia, United States - University Hospitals Case Medical Center, Case Western Reserve University
Cleveland, Ohio, United States
|
26 |
NCT01410123 |
Active, not recruiting |
Integrated Stepped Care for Unhealthy Alcohol Use in HIV |
- Liver Diseases, Alcoholic
- Alcoholism
- HIV
- Hepatitis C
|
- Other: Integrated Stepped Care (ISC)
- Other: Treatment as Usual
|
Interventional |
Not Applicable |
- Yale University
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- VA Office of Research and Development
|
Other / NIH / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- At risk drinking: Drinks per week
- Alcohol abuse or dependence: Drinks per week
- Moderate Alcohol + Liver Disease group: Abstinence.
- (and 2 more...)
|
319 |
All |
21 Years and older (Adult, Senior) |
NCT01410123 |
1105008544 U01AA020795 |
|
January 2013 |
July 2018 |
July 2018 |
August 4, 2011 |
January 10, 2018 |
|
- Washington DC VAMC
Washington, District of Columbia, United States - VAMC Atlanta
Atlanta, Georgia, United States - New York VAMC - New York Harbor Healthcare System
New York, New York, United States - (and 2 more...)
|
27 |
NCT01419314 |
Completed Has Results |
Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy |
- HIV
- AIDS
- Peripheral Neuropathy
- (and 2 more...)
|
- Device: Splinting application to the lower extremities
- Device: Splint liner application
|
Interventional |
Not Applicable |
- Texas Woman's University
- Harris County Hospital District
- DJO Incorporated
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Pain Scores at Week 3
- Pain Scores
- Sleep Quality/Quantity Scores (PSQI)
- (and 2 more...)
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT01419314 |
16196 |
|
August 2011 |
June 2012 |
June 2012 |
August 18, 2011 |
January 3, 2013 |
January 3, 2013 |
- Thomas Street Health Center-HCHD
Houston, Texas, United States
|
28 |
NCT01472354 |
Completed |
Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults |
|
- Behavioral: Leap-c group intervention
|
Interventional |
Not Applicable |
- University of Massachusetts, Worcester
- National Institute of Nursing Research (NINR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Decrease in decisional conflict related to HCV treatment 12 weeks post treatment
- Proportion of subjects electing HCV treatment 6 months after enrollment in the feasibility study.
- Increase in knowledge related to HCV treatment 12 weeks post treatment
- (and 4 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT01472354 |
S61110000013230 R21NR011132 |
LEAP-C |
October 2010 |
November 2012 |
November 2012 |
November 16, 2011 |
May 30, 2013 |
|
- University of Massachusetts Graduate School of Nursing
Worcester, Massachusetts, United States
|
29 |
NCT01399619 |
Completed Has Results |
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4) |
|
- Drug: PegIFN/RBV
- Drug: BI201335
- Drug: BI201335 24W
- Drug: Bi 201335
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sustained Virological Response (SVR12)
- Virological Response 24 Weeks Post Treatment (SVR24)
- Early Treatment Success (ETS)
- (and 8 more...)
|
310 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01399619 |
1220.19 2010-021734-59 |
|
September 2011 |
September 2013 |
June 2014 |
July 22, 2011 |
August 29, 2016 |
September 4, 2015 |
- 1220.19.0045 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States - 1220.19.0007 Boehringer Ingelheim Investigational Site
Palm Springs, California, United States - 1220.19.0031 Boehringer Ingelheim Investigational Site
San Francisco, California, United States - (and 68 more...)
|
30 |
NCT01419561 |
Recruiting |
History of the KSHV Inflammatory Cytokine Syndrome (KICS) |
- KSHV Inflammatory Cytokine Syndrome (KICS)
- KSHV
- HHV-8
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Assessment of the natural history of KICS, including the spectrum of clinical, laboratory and radiographic abnormalities seen in affected patients.
|
80 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01419561 |
110220 11-C-0220 |
|
August 17, 2011 |
|
|
August 18, 2011 |
November 28, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
31 |
NCT01452503 |
Completed |
Assessing Preference for 3 Female Condoms: A Comparative Evaluation of the PATH Woman's Condom, FC2 and the Reddy 6 |
|
- Device: Path Women's Condom
- Device: FC2 female condom
- Device: Reddy 6 female condom (V-Amour)
|
Interventional |
Not Applicable |
- FHI 360
- United States Agency for International Development (USAID)
- University of Witwatersrand, South Africa
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Preference of female condom by type
- Safety of each of the female condom types
- Function of each of the female condom types
|
170 |
Female |
18 Years and older (Adult, Senior) |
NCT01452503 |
9928 USAID |
|
May 2007 |
February 2008 |
April 2008 |
October 17, 2011 |
May 25, 2016 |
|
- Commercial City Clinic Department of Health
Durban, South Africa
|